News and Comments

Onyx (ONXX) Was Right All Along

  Monday, July 26, 2010

In October 2009, Onyx (ONXX) paid $276 million up front to acquire the privately held Proteolix to get to its multiple myeloma drug carfilzomib. It promised $535 million in future payments largely contingent on carfilzomib's approval. As usual, investors did not like Onyx paying money, because investors do not like any company to pay money to develop or acquire state-of-the- art products. When somebody hates something he sees everything in it with pessimism. Onyx put its hands on carfilzomib, which looked very promising for multiple myeloma cases resistant to current treatments. The breakthrough multiple myeloma drugs Velcade (bortezomib) and Revlimid (lenolidamide) could not prevent the cancer from recurring and failed to work at all on a large percentage of recurrent cancer.  More...


Recent Postings


Archive


Tags

Global Cell Therapeutics (GBT) SUNESIS PHARMACEUTICALS (SNSS) Agenus (AGEN) Ionis (IONS) Spike Therapeutics (ONCE) SERES THERAPEUTICS (MCRB) Biocryst (BCRX) Anadys (ANDS) Incyte (INCY) Inovio (INO) Gilead (GILD) INNOVIVA (INVA) Idenix (IDIX) Jazz Pharmaceuticals (JAZZ) Ocular Therapeutix (OCUL) REGULUS (RGLS) Sanofi (SNY) ImmunoGen (IMGN) Editas (EDIT) TOKAI (TKAOI) IDERA (IDRA) Alder Biopharmaceuticals (ALDR) OSI (OSIP) RenenxBio (RGNX) Agenus (AGEN GlaxoSmithKline (GSK) Sanofi (SNA) ACADIA (ACAD) Roche (RHHBY) Merck (MRK) ZALTRAP™ HALOZYME (HALO) Telaprevir Intrexon (XON) Theravance Bio Pharma (TBPH) C4 Therapeutics Exelixis (EXEL) Zerenex NOVOCURE (NVCR) ABBVIE (ABBV) Alnylam (ALNY) ADVENTRIX (ANX) Onyx (ONXX) Multiple Myeloma Ridaforolimus Mirati Therapeutics (MRTX) VANDA (VNDA) Human Genome Sciences (HGSI) Galena (GALE) Sangamo (SGMO) Herceptin Vitae Pharmaceuticals (VTAE) Tysabri Intercept (ICPT) Valeant Pharmaceuticals International (VRX) galapagos (GLPG) CRISPR Therapeutics (CRSP) Abbott Laboratories (ABT) OncoCyte (OCX) Seattle Genetics (SGEN) Biogen Idec (BIIB) ARGOS (ARGS) Illumina (ILMN) Elan (ELN) Dendreon (DNDN) Roche (ROCHE) Xoma (XOMA) Prolor Biotech (PBTH) Micromet (MITI) PTC Therapeutics (PTCT) Velcade (bortezomib) Genentech Anacor (ANAC) NEKTAR (NKTR)) Trastuzumab-DM1 Auspex (ASPX) LEXICON (LXRX) Sarepta (SRPT) Human Longevity (HLI) Intermune (ITMN) Dynavax (DVAX) MODERNA Endometrial Cancer AERIE PHARMACEUTICALS AGOS (ARGS) Bellicum (BLCM) Array Pharmaceuticals (ARRY) ARCA (ABIO) KITE (KITE) PORTOLA (PTLA) Benlysta (belimumab) CEMPRA (CEMP) CompuGen (CGEN) Ariad (ARIA) SYNTA (SNTA) GUARDIAN HEALTH Cytokinetics (CYTK) Regeneron (REGN) Bristol-Myers Squibb (BMY) Adaptimmune (ADAP) Aimmune Therapeutics (AIMT) BIOMARIN (BMRN) JUNO (JUNO) Rapamune JOUNCE THERAPEUTICS (JNCE) Ziofpharm (ZIOP) Sequenom (SQNM) Pluristem (PSTI) Prosensa (RNA) KERYX (KERX) Vertex (VRTX) Advaxis (ADXS) ISIS (ISIS) AstraZeneca (AZN) Revlimid (lenolidamide) Amgen (AMGN) Sanofi-Aventis (SAN) NANTKWEST (NK) Theravance (THRX)